PMID: 11918530Mar 29, 2002Paper

Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99

British Journal of Haematology
David K H WebbJudith M Chessells

Abstract

Between 1990 and 1999, 36 children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt), not associated with Down's syndrome, were diagnosed in Britain. A total of 31 children received intensive chemotherapy, six of whom proceeded to a bone marrow allograft in first remission, whereas two received an autograft. Of the 23 given chemotherapy only, four died of toxicity, 10 relapsed and nine are alive in first remission. Out of the 10 who relapsed, four are alive and disease-free following an allograft. Out of the 6 children given an allograft in first remission, two died of disease and four are alive in first remission. Both children given an autograft died of disease. Two children received an allograft without prior chemotherapy but died of toxicity. Three children received supportive care only, and one child survived. The overall survival was 51% at 5 years, and was superior in children with RAEBt (63%) compared with RAEB (28%, P = 0.03). Cytogenetics were available in 35 cases. Monosomy 7 was the most common abnormality (33% of cases). Survival in children with monosomy 7 was 22% at 5 years compared with 66% for the other patients (P = 0.05). Allowing for cytogenetics, outcomes of therapy appear...Continue Reading

References

Jan 1, 1992·Hematological Oncology·R F Ozols
Dec 1, 1987·Seminars in Oncology·G J TricotR Hoffman
Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
May 1, 1993·British Journal of Haematology·G H JacksonM M Reid
Jan 1, 1996·Cancer Genetics and Cytogenetics·T InabaM Nakagawa
Oct 16, 1999·British Journal of Haematology·H HasleK R Schultz
Nov 11, 1999·British Journal of Haematology·P D Emanuel
Mar 4, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·N L HarrisC D Bloomfield

❮ Previous
Next ❯

Citations

May 5, 2005·Current Treatment Options in Oncology·Charlotte Marie NiemeyerHenrik Hasle
Oct 28, 2008·International Journal of Hematology·Yuko HondaUNKNOWN From the MDS Committee, the Japanese Society of Pediatric Hematology
Oct 6, 2009·Bone Marrow Transplantation·V RochaE Gluckman
Jan 17, 2007·Current Opinion in Pediatrics·Henrik Hasle
Jan 9, 2008·Seminars in Hematology·Charlotte M Niemeyer, Irith Baumann
Feb 28, 2008·British Journal of Haematology·Charlotte Marie Niemeyer, Christian Peter Kratz
Jun 28, 2012·British Journal of Haematology·Akira KikuchiUNKNOWN Japanese Paediatric Myelodysplastic Syndrome (MDS) Study Group
May 11, 2011·British Journal of Haematology·Henrik Hasle, Charlotte M Niemeyer
Jul 21, 2006·Pediatric Blood & Cancer·Dorothy R BarnardUNKNOWN Children's Oncology Group
Apr 7, 2005·Bone Marrow Transplantation·J StarýUNKNOWN European Working Group on Myelodysplastic Syndrome (EWOG-MDS) and Pediatric Diseases Working Party of the EBMT
Jul 15, 2005·Genes, Chromosomes & Cancer·Ikuya SakaiMasaki Yasukawa
Nov 25, 2004·Hematology·Ching-Hon PuiCharlotte M Niemeyer
Mar 24, 2018·Molecular Biology Reports·Ameer HamzaDaniel Snower

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.